Abstract
Abacavir is an effective nucleoside analog reverse transcriptase inhibitor used to treat human immunodeficiency virus (HIV) infected patients. Its main side effect is hypersensitivity reaction (HSR). The incidence of the HSR is associated with ethnicity among patients exposed to abacavir, and retrospective and prospective studies show a significantly increased risk of abacavir-induced HSR in human leukocyte antigen (HLA)-B*57:01-carrying patients. Immunological studies indicated that abacavir interacts specifically with HLA-B*57:01 and changed the binding specificity between the HLA molecule and the HLA-presented endogenous peptide repertoire, leading to a systemic autoimmune reaction. HLA-B*57:01 screening, combined with patch testing, had clinically predictive value and cost-effective impact in reducing the incidence of abacavir-induced HSR regardless of the HLA-B*57:01 prevalence in the population. Therefore, the US Food and Drug Administration (FDA) and international HIV treatment guidelines recommend a routine HLA-B*57:01 screening prior to abacavir treatment to decrease false positive diagnosis and prevent abacavir-induced HSR. The studies of abacavir-induced HSR and the implementation of the HLA-B*57:01 screening in the clinic represent a successful example of the use of pharmacogenetics for personalized diagnosis and therapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Foster R H, Faulds D. Abacavir. Drugs, 1998, 55: 729–736
Hervey P S, Perry C M. Abacavir: a review of its clinical potential in patients with HIV infection. Drugs, 2000, 60: 447–479
Hughes A R, Spreen WR, Mosteller M, et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J, 2008, 8: 365–374
Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol, 2011, 71: 659–671
Hughes C A, Foisy M M, Dewhurst N, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother, 2008, 42: 387–396
Clay P G. The abacavir hypersensitivity reaction: a review. Clin Ther, 2002, 24: 1502–1514
Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther, 2001, 23: 1603–1614
Rodriguez-Novoa S, Soriano V. Current trends in screening across ethnicities for hypersensitivity to abacavir. Pharmacogenomics, 2008, 9: 1531–1541
Symonds W, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther, 2002, 24: 565–573
Cutrell A G, Hernandez J E, Fleming J W, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother, 2004, 38: 2171–2172
Peyrieere H, Nicolas J, Siffert M, et al. Hypersensitivity related to abacavir in two members of a family. Ann Pharmacother, 2001, 35: 1291–1292
Hetherington S, Hughes A R, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet, 2002, 359: 1121–1122
Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 2002, 359: 727–732
Arrizabalaga J, Rodriguez-Alcantara F, Castaner J L, et al. Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study). HIV Clin Trials, 2009, 10: 48–51
Berka N, Gill J M, Liacini A, et al. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta. Hum Immunol, 2012, 73: 164–167
Cao K, Hollenbach J, Shi X, et al. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol, 2001, 62: 1009–1030
Hughes A R, Mosteller M, Bansal A T, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics, 2004, 5: 203–211
Hughes D A, Vilar F J, Ward C C, et al. Pirmohamed M, Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics, 2004, 14: 335–342
Lee K W, Oh D H, Lee C, et al. Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens, 2005, 65: 437–447
Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med, 2008, 358: 568–579
Martin A M, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA, 2004, 101: 4180–4185
Middleton D, Hawkins B R, Williams F, et al. HLA class I allele distribution of a Hong Kong Chinese population based on high-resolution PCR-SSOP typing. Tissue Antigens, 2004, 63: 555–561
Middleton D, Menchaca L, Rood H, et al. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens, 2003, 61: 403–407
Moore C B, John M, James I R, et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science, 2002, 296: 1439–1443
Munderi P, Snowden W B, Walker A S, et al. Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART. Trop Med Int Health, 2011, 16: 200–204
Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J HIV Ther, 2003, 8: 36–41
Park W B, Choe P G, Song K H, et al. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? Clin Infect Dis, 2009, 48: 365–367
Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther, 2009, 13: 1–9
Phillips E J. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis, 2006, 43: 103–105
Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis, 2006, 43: 99–102
Saito S, Ota S, Yamada E, et al. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens, 2000, 56: 522–529
Sun H Y, Hung C C, Lin P H, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother, 2007, 60: 599–604
Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis, 2008, 46: 1111–1118
Martin S, Weltzien H U. T cell recognition of haptens, a molecular view. Int Arch Allergy Immunol, 1994, 104: 10–16
Lavergne S N, Park B K, Naisbitt D J. The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity. Curr Opin Allergy Clin Immunol, 2008, 8: 299–307
Pichler W J. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol, 2002, 2: 301–305
Pichler W J, Beeler A, Keller M, et al. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int, 2006, 55: 17–25
Pirmohamed M, Naisbitt D J, Gordon F, et al. The danger hypothesis—potential role in idiosyncratic drug reactions. Toxicology, 2002, 181–182: 55–63
Li J, Uetrecht J P. The danger hypothesis applied to idiosyncratic drug reactions. Handb Exp Pharmacol, 2010, 196: 493–509
Chessman D, Kostenko L, Lethborg T, et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity, 2008, 28: 822–832
Yang L, Chen J, He L. Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. PLoS Comput Biol, 2009, 5: e1000441
Illing P, Vivian J, Dudek N, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature, 2012, 486: 554–558
Ostrov D, Grant B, Pompeu Y, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA, 2012
Zucman D, Truchis P, Majerholc C, et al. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr, 2007, 45: 1–3
Nolan D. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects. Crit Rev Clin Lab Sci, 2009, 46: 153–165
Dervieux T, Bala M V. Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics, 2006, 7: 1175–1184
Rodriguez-Novoa S, Garcia-Gasco P, Blanco F, et al. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards. AIDS Res Hum Retroviruses, 2007, 23: 1374–1376
Schackman B R, Scott C A, Walensky R P, et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS, 2008, 22: 2025–2033
Lalonde R G, Thomas R, Rachlis A, et al. Successful implementation of a national HLA-B*5701 genetic testing service in Canada. Tissue Antigens, 2010, 75: 12–18
Nieves Calatrava D, Calle-Martin Ode L, Iribarren-Loyarte J A, et al. Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain. Enferm Infecc Microbiol Clin, 2010, 28: 590–595
Phillips E J, Wong G A, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS, 2005, 19: 979–981
Shear N H, Milpied B, Bruynzeel D P, et al. A review of drug patch testing and implications for HIV clinicians. AIDS, 2008, 22: 999–1007
Phillips E J, Sullivan J R, Knowles S R, et al. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS, 2002, 16: 2223–2225
Su Z, Ning B, Fang H, et al. Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn, 2011, 11: 333–343
ten Bosch J R, Grody W W. Keeping up with the next generation: massively parallel sequencing in clinical diagnostics. J Mol Diagn, 2008, 10: 484–492
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Guo, Y., Shi, L., Hong, H. et al. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci. China Life Sci. 56, 119–124 (2013). https://doi.org/10.1007/s11427-013-4438-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-013-4438-8